Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nemacide is a veterinary anthelmintic product whose reported active ingredient is diethylcarbamazine, a synthetic piperazine derivative anthelmintic used to treat infections with filarial nematodes and certain other parasitic worms in animals. Diethylcarbamazine’s mechanism is not fully defined but is thought to alter arachidonic acid metabolism and surface structures of microfilariae, making them more susceptible to host immune clearance and impairing neuromuscular function of the parasites. Nemacide is used in veterinary settings as a nematocidal and anthelmintic agent to control gastrointestinal and tissue-dwelling nematode infections, with dosing and formulation varying by species and indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nemacide.